BIOMAT Database Logo BIOMAT Database Logo

A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. 2011

Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
The Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom. frank.wegmann@path.ox.ac.uk

Prophylactic vaccination against HIV-1 sexual transmission will probably require antibody elicitation at genital mucosal surfaces. However, HIV-1 envelope glycoprotein (Env)-based antigens are weakly immunogenic, particularly when applied mucosally. The polyanion PRO 2000 is safe for human vaginal application, and thus may represent a potential formulating agent for vaginal delivery of experimental vaccine immunogens. Based upon its biochemical properties, we hypothesized that PRO 2000 might enhance mucosal immunogenicity of HIV-1 envelope glycoprotein (Env)-based antigens, promoting local and systemic immune responses. Vaginal immunization with Env-PRO 2000 resulted in significantly increased titres of Env-specific mucosal IgA and IgG in mice and rabbits, respectively, compared to Env alone, revealing modest but significant mucosal adjuvant activity for PRO 2000. In vitro, PRO 2000 associated with Env, protecting the glycoprotein from proteolytic degradation in human vaginal lavage. Unexpectedly, PRO 2000 antagonized TLR4 activation, suppressing local production of inflammatory cytokines. Since inflammation-mediated recruitment of viral target cells is a major risk factor in HIV-1 transmission, the immune modulatory and anti-inflammatory activities of PRO 2000 combined with its intravaginal safety profile suggests promise as an HIV-1 mucosal vaccine formulating agent.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D009282 Naphthalenesulfonates A class of organic compounds that contains a naphthalene moiety linked to a sulfonic acid salt or ester.
D011108 Polymers Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS). Polymer
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000282 Administration, Intravaginal The insertion of drugs into the vagina to treat local infections, neoplasms, or to induce labor. The dosage forms may include medicated pessaries, irrigation fluids, and suppositories. Administration, Vaginal,Drug Administration, Vaginal,Instillation, Vaginal,Intravaginal Administration,Vaginal Drug Administration,Vaginal Administration,Administration, Vaginal Drug,Administrations, Intravaginal,Administrations, Vaginal,Administrations, Vaginal Drug,Drug Administrations, Vaginal,Instillations, Vaginal,Intravaginal Administrations,Vaginal Administrations,Vaginal Drug Administrations,Vaginal Instillation,Vaginal Instillations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral

Related Publications

Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
Assessing human alloimmunization as a strategy for inducing HIV type 1 neutralizing anti-HLA responses.
November 2003, AIDS research and human retroviruses,
Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
Strategies for inducing effective neutralizing antibody responses against HIV-1.
November 2019, Expert review of vaccines,
Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
Mucosal antibody responses to HIV.
January 2009, Methods in molecular biology (Clifton, N.J.),
Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
A novel apoptosis-inducing anti-PSGL-1 antibody for T cell-mediated diseases.
July 2005, European journal of immunology,
Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
Recent progress in HIV vaccines inducing mucosal immune responses.
July 2014, AIDS (London, England),
Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
A novel carbodiimide coupling method for synthetic peptides. Enhanced anti-peptide antibody responses.
May 1990, Journal of immunological methods,
Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.
October 2021, Cancer letters,
Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
Alternative confirmatory strategy for anti-HIV antibody detection.
February 1992, Journal of virological methods,
Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
An agonist antibody that blocks autoimmunity by inducing anti-inflammatory macrophages.
February 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Frank Wegmann, and George Krashias, and Kerstin Lühn, and Karoliina Laamanen, and Sueli Vieira, and Simon A Jeffs, and Robin J Shattock, and Quentin J Sattentau
[Protective mucosal immunity and HIV-1 mucosal vaccine strategy].
July 2009, Bing du xue bao = Chinese journal of virology,
Copied contents to your clipboard!